首页> 美国卫生研究院文献>ecancermedicalscience >Highlights of the 16th St Gallen International Breast Cancer Conference Vienna Austria 20–23 March 2019: personalised treatments for patients with early breast cancer
【2h】

Highlights of the 16th St Gallen International Breast Cancer Conference Vienna Austria 20–23 March 2019: personalised treatments for patients with early breast cancer

机译:第16届圣加仑国际乳腺癌会议的重点2019年3月20-23日奥地利维也纳:针对早期乳腺癌患者的个性化治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 16th St Gallen International Breast Cancer Conference took place in Vienna for the third time, from 20–23 March 2019. More than 3000 people from all over the world were invited to take part in this important bi-annual critical review of the ‘state of the art’ in the primary care of breast cancer (BC), independent of political and industrial pressure, with the aim to integrate the most recent research data and most important developments in BC therapies since St Gallen International Breast Cancer Conference 2017, with the ultimate goal of drawing up a consensus for the current optimal treatment and prevention of BC.This year, the St Gallen Breast Cancer Award was won by Monica Morrow (Memorial Sloan Kettering Cancer Center, USA) for her extraordinary contribution in research and practise development in the treatment of BC. She opened the session with the lecture ‘Will surgery be a part of BC treatment in the future?’ Improved systemic therapy has decreased BC mortality and increased pathologic complete response (pCR) rates after neoadjuvant chemotherapy (NACT). Improved imaging and increased screening uptake have led to detect smaller cancers. These factors have highlighted two possible scenarios to omit surgery: for patients with small low-grade ductal carcinoma in situ (DCIS) and for those who have received NACT and had a clinical and radiological complete response. However, considering that 7%–20% of `low-risk’ DCIS patients have co-existing invasive cancer at diagnosis, that surgery has become progressively less morbid and less toxic than some systemic therapies with a lower cost-effectiveness ratio, and that identification of pathologic complete response (pCR) without surgery requires more intensive imaging follow-up (more biopsies, higher cost and more anxiety for the patient), surgery still appears to be an essential treatment for BC.The Umberto Veronesi Memorial Award went to Lesley Fallowfield (Brighton and Sussex Medical School, UK) for her important research and activity in the field of the development of patient outcome, of better communication skills and quality of life for women. In her lecture, she remarked on the importance of improving BC personalised treatments, especially through co-operation between scientists, always considering the whole woman and not just her breast disease. This award was given by Paolo Veronesi, after a moving introduction which culminated with the following words of Professor Umberto Veronesi:‘It is not possible to take care of the people’s bodies without taking care of their mind. My duty, the duty of all doctors, is to listen and be part of the emotions of those we treat every day’.
机译:第16届圣加仑国际乳腺癌大会于2019年3月20日至23日第三次在维也纳举行。来自世界各地的3000多人应邀参加了对``国家独立于政治和工业压力,是乳腺癌(BC)初级护理领域的``最新技术'',旨在整合自2017年圣加仑国际乳腺癌大会以来BC治疗的最新研究数据和最重要发展,最终达成共识,就目前的最佳治疗和预防BC达成最终目标。今年,圣加仑乳腺癌奖由莫妮卡·莫罗(Monica Morrow)(美国斯隆·凯特琳纪念癌症中心)以其在癌症研究和实践开发方面的杰出贡献而获得。 BC的治疗。她以“未来手术将成为BC治疗的一部分吗?”演讲作为开场会议,改进的全身治疗降低了BC死亡率,并提高了新辅助化疗(NACT)后的病理完全缓解率(pCR)。影像学的改善和筛查吸收的增加已导致发现较小的癌症。这些因素突显了两种可能省略手术的情况:对于小型低度原位导管癌(DCIS)的患者以及已接受NACT且临床和放射学完全缓解的患者。但是,考虑到7%–20%的“低风险” DCIS患者在诊断时并存浸润性癌症,因此与某些成本效益比较低的全身疗法相比,手术的病态性和毒性逐渐降低,并且无需手术即可识别病理完全缓解(pCR)需要更深入的影像学随访(对患者而言需要更多的活检,更高的费用和更多的焦虑),手术似乎仍是BC的基本治疗方法.Umberto Veronesi纪念奖授予了Lesley Fallowfield(英国布莱顿和苏塞克斯医学院)在发展患者预后,改善妇女的沟通技巧和生活质量方面的重要研究和活动方面,为她提供了重要的研究和活动。在演讲中,她谈到了改善BC个性化治疗的重要性,特别是通过科学家之间的合作,始终要考虑整个女人,而不仅仅是她的乳房疾病。这项奖项由保罗·韦罗内西(Paolo Veronesi)颁发,经过引人入胜的介绍,最后引述了翁贝托·韦罗内西(Umberto Veronesi)教授的以下话:“如果不照顾自己的思想,就不可能照顾人民的身体。我的职责是所有医生的职责,是倾听并成为我们每天治疗的人的情感的一部分。”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号